Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 30,654 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP George Lloyd sold 30,654 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $38.50, for a total value of $1,180,179.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Royalty Pharma Price Performance

RPRX stock traded up $0.17 during mid-day trading on Friday, reaching $38.60. 5,268,520 shares of the company’s stock were exchanged, compared to its average volume of 4,341,680. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. Royalty Pharma PLC has a 12-month low of $24.32 and a 12-month high of $41.24. The stock’s 50 day moving average is $38.30 and its 200 day moving average is $36.70. The company has a market cap of $22.28 billion, a price-to-earnings ratio of 29.24, a price-to-earnings-growth ratio of 2.02 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The business had revenue of $609.29 million during the quarter, compared to analysts’ expectations of $765.01 million. On average, research analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 10th. Investors of record on Friday, November 14th were given a dividend of $0.22 per share. The ex-dividend date was Friday, November 14th. This represents a $0.88 dividend on an annualized basis and a yield of 2.3%. Royalty Pharma’s dividend payout ratio (DPR) is presently 66.67%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Capital International Investors grew its stake in shares of Royalty Pharma by 24.4% during the third quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock worth $960,064,000 after purchasing an additional 5,332,074 shares in the last quarter. Swedbank AB lifted its holdings in Royalty Pharma by 0.4% during the 3rd quarter. Swedbank AB now owns 12,200,270 shares of the biopharmaceutical company’s stock worth $430,426,000 after buying an additional 42,800 shares during the last quarter. State Street Corp boosted its position in shares of Royalty Pharma by 0.8% during the 3rd quarter. State Street Corp now owns 10,272,753 shares of the biopharmaceutical company’s stock worth $362,423,000 after acquiring an additional 77,815 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Royalty Pharma by 2.2% during the 2nd quarter. Geode Capital Management LLC now owns 8,176,504 shares of the biopharmaceutical company’s stock worth $299,494,000 after acquiring an additional 177,036 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Royalty Pharma in the 2nd quarter valued at about $181,388,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on RPRX shares. Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. TD Cowen raised their price target on shares of Royalty Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Leerink Partners set a $45.00 target price on Royalty Pharma in a research note on Thursday, December 11th. Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Finally, The Goldman Sachs Group initiated coverage on Royalty Pharma in a research note on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.